CURB-65 Pneumonia Severity Score
- Introduced by
- W. Staniford Lim, et al.
- Year
- 2003
- Type
- Community-acquired pneumonia severity assessment
- Family
- Clinical scoring
What does it do?
CURB-65, derived and validated by Lim et al. in 2003, is a 5-point severity of illness score for community-acquired pneumonia (CAP).
It assesses confusion, urea nitrogen, respiratory rate, blood pressure, and age ≥65 years to stratify mortality risk and guide admission and treatment decisions.
The intuition behind the method
CURB-65 quantifies clinical observations and a single lab value to predict the severity of CAP-related organ dysfunction and mortality risk. The five components reflect different aspects of physiological derangement: altered mentation (cerebral hypoxia), elevated urea (renal dysfunction, dehydration), tachypnea (respiratory distress), hypotension (septic shock), and advanced age (frailty). Each point increases mortality risk substantially. A patient with CURB-65 = 0–1 can often be managed in the community with oral antibiotics, whereas CURB-65 ≥ 3 indicates severe pneumonia requiring hospitalization and possibly intensive care.
History
Lim and colleagues derived and validated CURB-65 in 2003 from UK and Spain cohorts to improve severity assessment in CAP beyond simple clinical impression. The score was adopted by the British Thoracic Society and European respiratory guidelines as the standard for CAP stratification. A simpler version (CRB-65) without urea was developed for use when lab values are unavailable. CURB-65 has remained stable and widely used for over 20 years, though emerging biomarkers (procalcitonin, lactate) offer complementary prognostic information.
When to use it
CURB-65 is applied at presentation in patients with suspected community-acquired pneumonia to stratify severity and guide disposition (outpatient vs. hospital) and treatment intensity (oral vs. IV antibiotics). It is widely used in emergency departments, urgent care, and primary care. CURB-65 is less applicable to hospital-acquired or ventilator-associated pneumonia.
Limitations and considerations
- Does not account for comorbidities (COPD, heart failure, renal disease) that increase mortality independent of pneumonia severity
- Urea is not universally available in point-of-care settings; clinical decision-making may proceed without it, reducing accuracy
- Respiratory rate, blood pressure, and confusion are subject to measurement variability and observer subjectivity
- Does not address clinical signs of severe sepsis (lactate, septic shock) or need for mechanical ventilation
- Lower specificity in very young or very old patients; CURB-65 ≥ 3 may underestimate risk in frail elderly
Source conditions do not replace independent scientific review or validation by an analysis engine.
Strengths
- Simple, rapid assessment using readily available clinical variables and a single lab value
- Strong prognostic discrimination: mortality risk scales predictably from 0 to > 15% across CURB-65 range
- Enables safe outpatient management of low-risk CAP, reducing unnecessary hospitalizations and costs
- Well-validated across diverse populations and geographic regions
- Reduces variability in treatment decisions compared to clinician gestalt alone
Applications
- Emergency department CAP triage: CURB-65 score guides admission vs. outpatient management and antibiotic choice
- Primary care pneumonia assessment: low CURB-65 supports safe outpatient oral antibiotic therapy
- Hospital-based pneumonia quality initiatives: monitoring CURB-65 distribution and outcomes to ensure appropriate resource use
- CAP research on diagnostic accuracy and treatment efficacy, stratifying by baseline severity
- Cost-effectiveness analysis: demonstrating how CURB-65-guided outpatient management reduces healthcare costs without compromising outcomes
How it works
How it works
A clinician obtains or assesses five variables: new-onset mental status changes (confusion), blood urea nitrogen (mmol/L), respiratory rate (breaths per minute), blood pressure (systolic and diastolic), and age ≥65 years. Confusion is defined as acute disorientation in person, place, or time.
Each variable is scored 0 or 1: confusion present = 1 point, urea ≥ 7 mmol/L = 1 point, respiratory rate ≥ 30 = 1 point, systolic BP < 90 or diastolic BP ≤ 60 = 1 point, age ≥ 65 = 1 point. Total CURB-65 ranges from 0 to 5.
CURB-65 0–1 = low risk (mortality < 2%), can treat as outpatient with oral antibiotics. CURB-65 2 = intermediate risk (mortality ~9%), consider hospitalization. CURB-65 3–5 = high risk (mortality > 15%), requires hospitalization and IV antibiotics; CURB-65 ≥ 4 warrants ICU evaluation.
Common pitfalls
- Using CURB-65 alone to make disposition decisions without clinical judgment; a patient with CURB-65 = 1 but severe comorbidity may still warrant admission.
- Forgetting to check urea and substituting gestalt judgment; urea adds critical prognostic information.
- Attributing low CURB-65 to good prognosis without considering rapid deterioration in the ensuing hours; CURB-65 is a snapshot at presentation.
- Applying CURB-65 to hospital-acquired pneumonia or immunocompromised hosts where different predictors apply.
Frequently asked questions
What if I don't have a urea result at the time of assessment?
Use CRB-65 (Confusion, Respiratory rate, Blood pressure, age ≥65), which omits urea. CRB-65 ≤ 1 is low risk; CRB-65 ≥ 2 is higher risk. However, when urea is available (within a few hours), incorporate it into CURB-65 for better accuracy.
Can I use CURB-65 to rule out CAP?
No. CURB-65 assesses severity in patients with confirmed CAP, not the probability that a patient has CAP. Diagnosis of pneumonia requires clinical suspicion and imaging (chest X-ray or CT); CURB-65 stratifies severity once diagnosis is made.
Is CURB-65 accurate in patients with COPD or other lung disease?
CURB-65 was derived in mixed CAP populations including COPD patients. However, COPD patients with CAP may deteriorate faster and warrant more aggressive treatment even if CURB-65 is low. Use CURB-65 as a guide, not a strict rule, in patients with comorbidity.
What if CURB-65 increases during hospitalization?
Rising CURB-65 during treatment (e.g., new confusion, worsening renal function, hypotension) indicates clinical deterioration and need for escalation of care, including consideration of ICU transfer and broader antibiotic coverage.
Related methods
Sources
Lim, W. S., van der Eerden, M. M., Laing, R., et al. (2003). Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax, 58(5), 377-382.
Open DOI referenceCopied.Capelastegui, A., España, P. P., Quintana, J. M., et al. (2006). Validation of a community-acquired pneumonia severity score. European Respiratory Journal, 27(2), 405-413.
Open publication referenceCopied.